The estimated Net Worth of David L Lowrance is at least $2.46 millió dollars as of 28 December 2023. Mr. Lowrance owns over 10,000 units of Savara Inc stock worth over $1,478,974 and over the last 15 years he sold SVRA stock worth over $281,208. In addition, he makes $699,033 as Chief Financial Officer és Secretary at Savara Inc.
David has made over 9 trades of the Savara Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 10,000 units of SVRA stock worth $47,100 on 28 December 2023.
The largest trade he's ever made was exercising 31,894 units of Savara Inc stock on 2 January 2018 worth over $48,160. On average, David trades about 5,586 units every 133 days since 2010. As of 28 December 2023 he still owns at least 342,355 units of Savara Inc stock.
You can see the complete history of Mr. Lowrance stock trades at the bottom of the page.
David L. Lowrance CPA serves as Chief Financial Officer, Secretary of the Company. He has served as Savara’s Chief Financial Officer since November 2016. From September 2014 to October 2016, Mr. Lowrance served as the Chief Financial Officer and Treasurer of Edgemont Pharmaceuticals, a fully-integrated specialty pharmaceutical company with multiple marketed products in the CNS space. From April 2011 to September 2014, Mr. Lowrance served as the Chief Financial Officer and Secretary of Acucela Inc., a clinical-stage biotechnology company that specializes in ophthalmic therapeutics, where he was responsible for overseeing all aspects of Acucela’s day-to-day operations, business development and growth endeavors, investor relations and corporate communications. While at Acucela, Mr. Lowrance helped lead a $162 million international IPO, with a listing on the Tokyo Stock Exchange. From March 2003 to April 2011, Mr. Lowrance was Vice President and Chief Financial Officer of Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on commercializing branded prescription products, where he oversaw all aspects of finance and accounting, business and growth strategy and product development. Mr. Lowrance, a CPA, holds a B.B.A. in Accounting from the University of Georgia.
As the Chief Financial Officer és Secretary of Savara Inc, the total compensation of David Lowrance at Savara Inc is $699,033. There are 1 executives at Savara Inc getting paid more, with Dr. Badrul A. Chowdhury M.D., Ph.D. having the highest compensation of $816,959.
David Lowrance is 52, he's been the Chief Financial Officer és Secretary of Savara Inc since 2017. There are 8 older and 3 younger executives at Savara Inc. The oldest executive at Savara Inc is Richard Hawkins, 71, who is the Independent Director.
David's mailing address filed with the SEC is ONE SUMMIT SQUARE,, 1717 LANGHORNE NEWTOWN ROAD, SUITE 300, LANGHORNE, PA, 19047.
Over the last 7 years, insiders at Savara Inc have traded over $2,203,958 worth of Savara Inc stock and bought 6,103,761 units worth $15,290,245 . The most active insiders traders include Forest Baskett, Scott D Sandell és Anthony A. Jr. Florence. On average, Savara Inc executives and independent directors trade stock every 29 days with the average trade being worth of $348,922. The most recent stock trade was executed by Matthew Pauls on 28 December 2023, trading 84,000 units of SVRA stock currently worth $395,640.
savara pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. the company’s lead product, aerovanc is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant staphylococcus aureus (mrsa) infection in patients with cystic fibrosis (cf). for more information, please see savara’s website at www.savarapharma.com or www.aerovanc.com
Savara Inc executives and other stock owners filed with the SEC include: